Traws Pharma gets HREC approval for Phase 2 COVID trials of ratutrelvir; top-line data expected year-end 2025

Traws Pharma, Inc.

First Phase 2 non-inferiority trial compares ratutrelvir 600 mg QD for 10 days vs PAXLOVID 5-day regimen in newly diagnosed COVID subjects.
Second single-arm trial tests ratutrelvir in PAXLOVID-ineligible patients; both trials expect top-line results by year-end 2025.
Ratutrelvir is ritonavir-free, once-daily for 10 days, aiming to reduce clinical rebound and Long COVID risk.
Pfizer reported $427M PAXLOVID sales in Q2 2025 (+70% YoY), highlighting continued market need for COVID treatments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.